Capricor Therapeutics, Inc. (NASDAQ:CAPR) is among the top losers of the stock market today, sinking -13.51% or (-0.05 points) to $0.32 from its previous close of $0.37. Does this decline mean it the best stock to buy right now? The shares seem to have an active trading volume day with a reported 422620 contracts so far this session. CAPR shares had a relatively better volume day versus average trading capacity of 200.79 thousand shares, but with a 23.43 million float and a -11.48% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for CAPR stock indicates that the average analyst price target is $3.5 per share. This means the stock has a potential increase of 993.75% from where the CAPR share price has been trading recently which is between $0.3661 and $0.3888. There are some brokerage firms that offer lower targets than the average, with one of them, even setting their price target at $3.5.
The shorts are climbing into Capricor Therapeutics, Inc. (CAPR) stock. The latest set of short interest data was released on 30 April 2019, and the numbers show a rise in short interest in CAPR shares. While short interest still represents only 1.23% of CAPR’s float, the number of shares shorted have risen by 94381. The number of shares shorted advanced to 383356 shares, up from 288975 shares during the preceding fortnight. With average daily trading volumes at 103859 shares, days to cover increased to about 1 days. The most recent news story about the stock that appeared in Yahoo Finance‘s news section was titled “Capricor Therapeutics (CAPR) Reports Q1 Loss, Lags Revenue Estimates” and dated May 13, 2019.
During the recent trading session for Capricor Therapeutics, Inc. (NASDAQ:CAPR), the company witnessed their stock drop by $-0.1 over a week and tumble down $-0.21 from the price 20 days ago. When compared to their established 52-week high of $1.58, the high they recorded in their recent session happens to be lower. Their established 52-week high was attained by the company on 07/16/18. The recent low of $0.31 stood for a -79.75% since 12/27/18, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 1.54 is also allocated to the stock. Since the beta is greater than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to.
Looking at the current readings for Capricor Therapeutics, Inc., the two-week RSI stands at 19.4. This figure suggests that CAPR stock, for now, is overbought, meaning that the shares are not stable in terms of price movement. The stochastic readings, on the other hand, based on the current CAPR readings is similarly very revealing as it has a stochastic reading of 13.37% at this stage. This figure means that CAPR share price today is being overbought.
Technical chart claims that Capricor Therapeutics, Inc. (CAPR) would settle between $0.38/share to $0.4/share level. However, if the stock price goes below the $0.36 mark, then the market for Capricor Therapeutics, Inc. becomes much weaker. If that happens, the stock price might even plunge as low as $0.35 for its downside target. The stock is currently in the red zone of MACD, with the indicator reading -0.04. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.
Analysts at Maxim Group lowered their recommendation on shares of CAPR from Buy to Hold in their opinion released on December 26. H.C. Wainwright analysts again handed out a Buy recommendation to Capricor Therapeutics, Inc. (NASDAQ:CAPR) stock but they lifted target price for the shares in a flash note issued to investors on January 26. The target price has been raised from $6.50 to $8.60. Analysts at H.C. Wainwright are sticking to their Buy stance. However, on September 15, they lifted price target for these shares to $6.50 from $2.15.
CAPR equity has an average rating of 2.5, with the figure leaning towards a bullish end. 2 analysts who tracked the company were contacted by Reuters. Amongst them, 1 rated the stock as a hold while the remaining 1 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while no rated it as a sell. 1 analysts rated Capricor Therapeutics, Inc. (NASDAQ:CAPR) as a buy or a strong buy while not a single analyst advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.
Moving on, CAPR stock price is currently trading at 0X forward 12-month Consensus EPS estimates, and its P/S ratio is 7.68 while for the average stock in the same group, the multiple is 42.11.
Capricor Therapeutics, Inc. (CAPR)’s current-quarter revenues are projected to climb by nearly -45% to hit $0.22 million, based on current Zacks Consensus Estimate. The firm’s full-year revenues are expected to expand by over -46.14% from $1.67 million to a noteworthy $0.9 million. At the other end of the current quarter income statement, Capricor Therapeutics, Inc. is expected to see its adjusted earnings surge by roughly 42.86% to hit $-0.08 per share. For the fiscal year, CAPR’s earnings are projected to climb by roughly 42.31% to hit $-0.3 per share.